Scott Rocklage

Scott M. Rocklage, Ph.D. joined 5AM Ventures in 2003 as a Venture Partner and became a Managing Partner in 2004. Dr. Rocklage has over 20 years of healthcare management experience with strategic leadership responsibilities that have led to the successful approval of three U.S. New Drug Applications by the FDA (Omniscan™, Teslascan® and Cubicin®), and entered six drug candidates into clinical trials. Dr. Rocklage has served as Chairman and CEO of Cubist Pharmaceuticals, President and CEO of Nycomed Salutar, President, CEO and Chairman of Nycomed Interventional and has also held various R&D positions at Salutar and Catalytica.

Dr. Rocklage currently serves as Board Chairman of Achaogen, Relypsa and Semprus as well as on the Boards of WaveRx, Pulmatrix and Variation and the Board of Associates at the Whitehead Institute. Dr. Rocklage was formerly Executive Chairman of Ilypsa (acquired by Amgen) and Miikana (acquired by EntreMed).

Dr. Rocklage received his B.S. in Chemistry from the University of California, Berkeley, and his Ph.D. in Chemistry from the Massachusetts Institute of Technology. Dr. Rocklage is based in the Waltham, MA office.